EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Patrick M Forde iD, Jonathan D Spicer, Mariano Provencio, Tetsuya Mitsudomi, Mark M Awad, Changli Wang, Shun Lu, Enriqueta Felip, Scott J Swanson, Julie R Brahmer, Keith Kerr, Janis M Taube und 16 weitere

New England Journal of Medicine · 21.08.2025 · 393 (8) · 741-752

DOI: 10.1056/nejmoa2502931 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 21.08.2025. Verfasst von Patrick M Forde und 27 weiteren Autor:innen. Beteiligte Einrichtung: Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 283-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyNivolumabAdultAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantSurvival AnalysisImmune Checkpoint InhibitorsNeoplasm StagingPneumonectomyPathologic Complete ResponseFollow-Up StudiesTime FactorsSurvival RateAged, 80 and over

Substanzen

NivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin.
  • McGill University Health Centre, Montreal.
  • Hospital Universitario Puerta de Hierro, Madrid.
  • Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, Japan.
  • Memorial Sloan Kettering Cancer Center, New York.
  • Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

ORCID-Profile: Patrick M Forde

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Forde, P. M., Spicer, J. D., Provencio, M., Mitsudomi, T., Awad, M. M., Wang, C., Lu, S., Felip, E., Swanson, S. J., Brahmer, J. R., Kerr, K., Taube, J. M., Ciuleanu, T. E., Tanaka, F., Saylors, G. B., Chen, K. N., Ito, H., Liberman, M., Martin, C., …, & CheckMate 816 Investigators (2025). Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. New England Journal of Medicine, 393(8), 741-752. https://doi.org/10.1056/nejmoa2502931

Vancouver

Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. New England Journal of Medicine. 2025;393(8):741-752. doi:10.1056/nejmoa2502931

BibTeX
@article{Forde2025,
  author = {Forde, Patrick M and Spicer, Jonathan D and Provencio, Mariano and Mitsudomi, Tetsuya and Awad, Mark M and Wang, Changli and Lu, Shun and Felip, Enriqueta and Swanson, Scott J and Brahmer, Julie R and Kerr, Keith and Taube, Janis M and Ciuleanu, Tudor-Eliade and Tanaka, Fumihiro and Saylors, Gene B and Chen, Ke-Neng and Ito, Hiroyuki and Liberman, Moishe and Martin, Claudio and Broderick, Stephen and Wang, Lily and Cai, Junliang and Duong, Quyen and Meadows-Shropshire, Stephanie and Fiore, Joseph and Bhatia, Sumeena and Girard, Nicolas and CheckMate 816 Investigators, CheckMate 816 Investigators},
  title = {Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {8},
  pages = {741--752},
  doi = {10.1056/nejmoa2502931}
}
Kostenlos starten →